* If you want to update the article please login/register
Factor XIa's Modulation of Factor XIa may provide a novel systemic anticoagulation therapy with the ability to enhance the risk-benefit profile associated with existing anticoagulants due to greater efficacy or a cleaner bleeding profile. On day 1, participants received a single oral dose of milvexian followed by a washout on days 2 and 3. Participants in period 2 received multiple oral doses of itraconazole or diltiazem with a single dose of milvexian. The Diltiazem co-administration also increased milvexian exposure; AUC_, and C _24 were 38, and 64 percent higher; and mean C _max was 9. 6% higher than milvexian alone. Following co-administration of itraconazole, a modest rise in milvexian exposure was observed, but a modest increase was observed with diltiazem, which was consistent with drug absorption/elimination.
Source link: https://doi.org/10.1007/s40119-022-00266-6
The aim of this study was to investigate the effect of a very low dose of diltiazem on tacrolimus intake during the first week post-kidney transplantation, among cytochrome P450 3A5 expressers who did not receive diltiazem, CYP3A5 nonexpressers who did not receive diltiazem, CYP3A5 expressers who did not receive diltiazem CYP3A5 expressers who did not receive diltiazem diazem dazem cytochrome P4503A5 expressers who did not receive CYP3A5 expressers who did not receive cytom CYP3A5 expressers who did not receive dazem CYP3A5 expressers who did not receives who did not receive dazem, CYP3A5 expressers who did not receives who did In conclusion, coadministration of diltiazem 30 mg twice daily may be useful in raising tacrolimus exposure early after kidney transplantation among CYP3A5 expressers.
Source link: https://doi.org/10.1038/s41598-022-18552-7
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions